ADMA Biologics, Inc. (ADMA) — Fair Value Analysis

Base-case fair value (P50): $10.04 · Current price: $8.73 · Verdict: Fairly Valued

Is ADMA overvalued based on Monte Carlo simulations?

The Verdict on ADMA

Based on our proprietary Monte Carlo simulations, ADMA BIOLOGICS INC (ADMA) is currently Fairly Valued. Our analysis indicates a median fair value (P50) of $10.04 for ADMA, which suggests an +14.9% potential relative to its current price of $8.73. This assessment is derived from thousands of forward-looking scenarios, weighing various operational and financial factors unique to the company within the Healthcare sector. While the current price sits below our P50 target, the overall distribution of potential outcomes leads to a balanced "Fairly Valued" verdict, suggesting that the stock is appropriately priced given its risk-reward profile without a significant directional bias.

How ADMA stacks up against Healthcare

ADMA's operational and financial health is currently assessed as "average" within the Healthcare sector. This average quality tier is a key input into our Monte Carlo simulations, influencing the range and probability of future cash flows and, consequently, the company's intrinsic value. The simulation, taking into account this average quality, still projects a median fair value of $10.04, standing above the current market price of $8.73. Despite the projected +14.9%, the "average" quality tier implies that while upside is present, the company may not possess the robust fundamentals or competitive advantages that would warrant a "Undervalued" rating at this price point within a rigorous Monte Carlo framework.

What this means for investors

For investors considering ADMA, the Fairly Valued verdict, combined with a median fair value of $10.04 and +14.9% relative to $8.73, suggests a balanced outlook. While there's a statistical edge for upside, the "average" quality tier indicates a balanced risk profile. Investors seeking significant undervaluation might look elsewhere, but those comfortable with a company holding an average quality tier in Healthcare could view the +14.9% as a compelling opportunity within a fairly valued stock. FairCurve's Monte Carlo analysis provides this nuanced view, moving beyond simple multiples. Sign up for a free FairCurve account to see the full bear and bull distribution for ADMA and track its fair value as new fundamental data is released.